AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial

AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit Amgen Inc (NASDAQ: AMGN) with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity. AstraZeneca’s AZD5991 belongs to the same class therapy. The trial suspension, noted on, came on October 19: “The study has been put on hold to allow further evaluation of safety-related information,”

Leave a Reply

Your email address will not be published. Required fields are marked *